Patents by Inventor Joseph P. Vacca

Joseph P. Vacca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HIV integrase inhibitors
    Patent number: 7968564
    Abstract: Tricyclic compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R1, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: April 15, 2010
    Date of Patent: June 28, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph P. Vacca, Linda S. Payne, Richard C. A. Isaacs
  • HCV NS3 Protease Inhibitors
    Publication number: 20110028494
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: July 28, 2006
    Publication date: February 3, 2011
    Inventors: M. Katharine Holloway, Nigel J. Liverton, John A. McCauley, Michael T. Rudd, Joseph P. Vacca, Steven W. Ludmerer, David B. Olsen
  • HCV NS3 protease inhibitors
    Patent number: 7879797
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: February 1, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: M. Katharine Holloway, Nigel J. Liverton, Steven W. Ludmerer, John A. McCauley, David Olsen, Michael T. Rudd, Joseph P. Vacca
  • P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN
    Publication number: 20110003822
    Abstract: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.
    Type: Application
    Filed: October 29, 2008
    Publication date: January 6, 2011
    Inventors: Christopher S. Burgey, Diem N. Nguyen, Daniel Paone, Craig M. Potteiger, Joseph P. Vacca
  • HCV NS3 Protease Inhibitors
    Publication number: 20100317623
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: October 19, 2007
    Publication date: December 16, 2010
    Inventors: Nigel J. Liverton, Vincenzo Summa, Joseph P. Vacca
  • HCV NS3 Protease Inhibitors
    Publication number: 20100298210
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use treating or preventing HCV infections.
    Type: Application
    Filed: October 19, 2007
    Publication date: November 25, 2010
    Inventors: Nigel J. Liverton, Vincenzo Summa, Joseph P. Vacca, Maria Emilia Di Francesco, Marco Pompei
  • HCV NS3 Protease Inhibitors
    Publication number: 20100286185
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: October 23, 2007
    Publication date: November 11, 2010
    Inventors: Nigel J Liverton, Joseph P. Vacca, John A. McCauley, Joseph J. Romano, Michael T. Rudo
  • P2X3 RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN
    Publication number: 20100266714
    Abstract: The subject invention relates to novel P2X3 receptor antagonists that play a critical role in treating disease states associated with pain, in particular peripheral pain, inflammatory pain, or tissue injury pain that can be treated using a P2X3 receptor subunit modulator.
    Type: Application
    Filed: October 29, 2008
    Publication date: October 21, 2010
    Inventors: Christopher S Burgey, Diem Nguyen, Zhengwu Deng, Daniel V. Paone, Craig M. Potteiger, Joseph P. Vacca
  • Cyclic ketal beta-secretase inhibitors for the treatment of alzheimer's disease
    Patent number: 7816378
    Abstract: The present invention is directed to cyclic ketal compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Grant
    Filed: July 28, 2006
    Date of Patent: October 19, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Philippe G. Nantermet, Joseph P. Vacca
  • HIV INTEGRASE INHIBITORS
    Publication number: 20100204201
    Abstract: Tricyclic compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R1, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: April 15, 2010
    Publication date: August 12, 2010
    Inventors: Joseph P. Vacca, Linda S. Payne, Richard C.A. Isaacs
  • TRICYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS
    Publication number: 20100160334
    Abstract: The present invention is directed to compounds of Formula I: I (where A1, A2, B1, B2, B3, B4, D1, D2, J, K, T, U, V, W, X, Y, Z, R4, R5a, R5b, R5c, m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Application
    Filed: March 5, 2010
    Publication date: June 24, 2010
    Inventors: Ian M. Bell, Steven N. Gallicchio, Graig A. Stump, Cory R. Theberge, Joseph P. Vacca, C. Blair Zartman, Xufang Zhang
  • HIV integrase inhibitors
    Patent number: 7741315
    Abstract: Tricyclic compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R1, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: May 5, 2006
    Date of Patent: June 22, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Joseph P. Vacca, John S. Wai, Linda S. Payne, Richard C. A. Isaacs, Richard Pracitto
  • HCV NS3 PROTEASE INHIBITORS
    Publication number: 20100093779
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: October 22, 2007
    Publication date: April 15, 2010
    Inventors: Nigel J. Liverton, Joseph P. Vacca, John A. McCauley, Joseph J. Romano, Michael T. Rudd
  • HIV PROTEASE INHIBITORS
    Publication number: 20100093811
    Abstract: Compounds of Formula I are disclosed: (I), wherein XA, k, R1, R2, R3, R4, R5, R5A, R6, R6A, R7 and R8 are defined herein. The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: September 22, 2008
    Publication date: April 15, 2010
    Inventors: Craig A. Coburn, Joseph P. Vacca, Hemaka A. Rajapakse, Kristen L.G. Jones, Philippe Nantermet, James C. Barrow, Keith P. Moore, Steven S. Sharik, Cory Theberge, Abbas M. Walji
  • Tricyclic anilide spirolactam CGRP receptor antagonists
    Patent number: 7696192
    Abstract: The present invention is directed to compounds of Formula I: I (where A1, A2, B1, B2, B3, B4, D1, D2, J, K, T, U, V, W, X, Y, Z, R4, R5a, R5b, R5c, m and n are defined herein) useful as antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as headache, migraine and cluster headache. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: September 6, 2005
    Date of Patent: April 13, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ian M. Bell, Steven N. Gallicchio, Craig A. Stump, Cory R. Theberge, Joseph P. Vacca, C. Blair Zartman, Xufang Zhang
  • Cyclic Ketal Beta-Secretase Inhibitors for the Treatment of Alzheimer's Disease
    Publication number: 20090176836
    Abstract: The present invention is directed to cyclic ketal compounds of formula (I) which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.
    Type: Application
    Filed: July 28, 2006
    Publication date: July 9, 2009
    Inventors: Philippe G. Nantermet, Joseph P. Vacca
  • HIV integrase inhibitors
    Patent number: 7538112
    Abstract: Hydroxy-substituted pyrazinopyrrolopyridazine dione compounds are inhibitors of HIV integrase and inhibitors of HIV replication. In one embodiment, the dione compounds are of Formula (I) wherein R1, R2, R3, R4, R5, R6 and R7 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Grant
    Filed: May 3, 2005
    Date of Patent: May 26, 2009
    Assignee: Merck & Co., Inc.
    Inventors: John S. Wai, Joseph P. Vacca, Linghang Zhuang, Boyoung Kim, Terry A. Lyle, Catherine M. Wiscount, Melissa S. Egbertson, Lou Anne Neilson, Mark Embrey, Thorsten E. Fisher, Donnette D. Staas
  • HCV NS3 PROTEASE INHIBITORS
    Publication number: 20090124661
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: December 1, 2008
    Publication date: May 14, 2009
    Applicant: MERCK & CO., INC.
    Inventors: M. Katharine HOLLOWAY, Nigel J. LIVERTON, Steven W. LUDMERER, John A. MCCAULEY, David B. OLSEN, Michael T. RUDD, Joseph P. VACCA, Charles J. MCINTYRE
  • HCV NS3 protease inhibitors
    Publication number: 20090075869
    Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.
    Type: Application
    Filed: April 28, 2006
    Publication date: March 19, 2009
    Inventors: M. Katharine Holloway, Nigel J. Liverton, Steven W. Ludmerer, John A. McCauley, David Olsen, Michael T. Rudd, Joseph P. Vacca
  • HIV INTEGRASE INHIBITORS
    Publication number: 20090054399
    Abstract: Tricyclic compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R1, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.
    Type: Application
    Filed: May 5, 2006
    Publication date: February 26, 2009
    Inventors: Joseph P. Vacca, John S. Wai, Linda S. Payne, Richard C.A. Isaacs, Wei Han, Melissa Egbertson, Richard Pracitto